Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on RVNC. HC Wainwright lowered shares of Revance Therapeutics from a strong-buy rating to a hold rating in a report on Tuesday, August 13th. Stifel Nicolaus lowered their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a buy rating for the company in a research report on Friday, August 9th. Guggenheim reissued a neutral rating on shares of Revance Therapeutics in a research report on Monday, August 12th. William Blair reissued a market perform rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Barclays reissued an equal weight rating and set a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $10.50.

Revance Therapeutics Stock Performance

RVNC opened at $5.30 on Monday. The firm’s fifty day moving average is $5.42 and its two-hundred day moving average is $4.27. The firm has a market cap of $555.55 million, a PE ratio of -1.46 and a beta of 1.00. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $13.12.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. The company’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.80) earnings per share.

Institutional Trading of Revance Therapeutics

Large investors have recently added to or reduced their stakes in the company. Capital World Investors lifted its stake in Revance Therapeutics by 16.8% in the first quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after acquiring an additional 2,006,459 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Revance Therapeutics by 342.1% during the 1st quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 163,809 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Revance Therapeutics during the 4th quarter worth about $93,000. Integral Health Asset Management LLC acquired a new stake in shares of Revance Therapeutics during the 2nd quarter worth about $1,285,000. Finally, Vanguard Group Inc. lifted its stake in shares of Revance Therapeutics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after buying an additional 328,781 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.